{"filing":{"accession_number":"0001193125-26-379423","cik":"0001737287","ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-08-31","primary_document":"d522964d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526379423/d522964d8k.htm"},"events":[{"id":31185,"run_id":28604,"accession_number":"0001193125-26-379423","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Geoffrey Parker, the Executive Vice President and Chief Financial Officer (principal financial officer), provided notice of retirement effective November 6, 2026. The departure of a CFO is a material executive change that would affect investor assessment of the company's financial leadership and continuity. This is a clear exec_departure event under Item 5.02(b).","company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34003,"accession_number":"0001193125-26-379423","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"Geoffrey Parker, the Executive Vice President and Chief Financial Officer (principal financial officer), provided notice of retirement effective November 6, 2026. The departure of a CFO is a material executive change that would affect investor assessment of the company's financial leadership and continuity. This is a clear exec_departure event under Item 5.02(b).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T12:45:47.058043+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34003,"accession_number":"0001193125-26-379423","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"Geoffrey Parker, the Executive Vice President and Chief Financial Officer (principal financial officer), provided notice of retirement effective November 6, 2026. The departure of a CFO is a material executive change that would affect investor assessment of the company's financial leadership and continuity. This is a clear exec_departure event under Item 5.02(b).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T12:45:47.058043+00:00","company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","filing_date":"2026-09-02"}]}